Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 17, 2026Annals of HematologyOpen Access

Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease

View Full Paper
Ask AI
Bookmark
Share

Authors

CBChristina BrummerKEKatja EvertFKFelix Keil

Discussion

Loading...

Member takes

Overview

Case report highlights the safety and effectiveness of tagraxofusp in treating BPDCN in patients with chronic kidney disease, suggesting a viable treatment option.

Key Points

  • The aim is to demonstrate the efficacy and safety of tagraxofusp in a patient with BPDCN and advanced chronic kidney disease.
  • Case report of a 79-year-old male with BPDCN and chronic kidney disease.
  • Administered tagraxofusp using a dose-reduced protocol.
  • Monitored treatment response through skin and bone marrow biopsies.
  • Achieved dermatologic complete response and partial remission of bone marrow infiltration.
  • Treatment disruption led to normalization of kidney function.
  • Sustained response lasted for 8 months before relapse.

Cite This Study

Brummer et al. (2026) studied this question.

synapsesocial.com/papers/696b25a9d2a12237a93490c2https://doi.org/10.1007/s00277-026-06794-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports2024 · 2 citations
  2. 2Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm2025
  3. 3Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm2025
  4. 4Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations2024 · 3 citations
  5. 5Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm2026 · 5 citations